Down 13.1% today, more than its biotech peers' 2.4%; no story names it yet.
Down 56% since Oct 20
Down 56% so far from Oct 20 to Nov 2.
−3Long-term trend
Follow BCAX's trial news. Pro members can get an alert when Bicara Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 19.1% a day with no profit behind it |
| Latest filing | 10-Q, Aug 11 |
TodayNo story names it yet.
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed -3.5% on average, higher 2 of 4 times.
About 14 quarters
CEO Ryan Cohlhepp sold 17,500 shares on Sep 8, under a planned sale. 27 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
BCAX is #244 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 244 |
Reports Mon Nov 9, before the open (in 7 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase was primarily due to costs associated with the ongoing FORTIFI-HN01 pivotal trial, as well as the company’s ongoing Phase 1/1b dose expansion cohorts, and an increase in personnel costs.”
BCAX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primarily due to additional personnel costs and professional fees associated with expanding the organization as we advance in a pivotal study and prepare for potential commercialization.”
From its results filing (SEC filing · Aug 11)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 11, 2026 | -17.8% | -14.3% | -10.1% |
| May 11, 2026 | -0.4% | +1.5% | -10.4% |
| Mar 30, 2026 | +4.1% | +3.6% | +13.5% |
Officers and directors with a Form 4 in the last 12 months.
In ETFs: BCAX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
BCAX scores -6 today, which Breakaway calls Poor. It is #244 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 56% so far from Oct 20 to Nov 2. Cash lasts about 14 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BCAX scores -6 today, which Breakaway calls Poor (below zero). That is #244 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BCAX's -6.
Reports Mon Nov 9, before the open, a date the company confirmed. BCAX closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.